Download PDF

1. Company Snapshot

1.a. Company Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's.


ACADIA Pharmaceuticals Inc.was founded in 1993 and is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on ACAD

ACADIA Pharmaceuticals Inc.'s recent performance was negatively impacted by mixed institutional investor activity. While some firms, such as Bank of America, upgraded the stock to 'Buy' citing an improved risk-reward profile, others, like First Trust Advisors LP, reduced their stake by 20.2%. The company's upcoming clinical readouts, including remlifanserin ADP data, may influence investor sentiment. With a consensus rating of "Moderate Buy" from twenty brokerages, ACADIA Pharmaceuticals faces both optimism and caution from analysts. Its Q4 2025 earnings call revealed $0.16 per share, beating estimates.

1.c. Company Highlights

2. ACADIA Pharmaceuticals' Strong Q4 2025 Earnings: A Closer Look

ACADIA Pharmaceuticals reported adjusted total revenues of $298 million in Q4 2025, a 16% increase from the prior year, and $1.08 billion in adjusted 2025 revenue, a 14% growth from the prior year. The company's earnings per share (EPS) came out at $1.6, significantly beating analyst estimates of $0.12. NUPLAZID net sales reached $189 million in Q4 and $692 million for the full year, with 17% and 15% year-over-year growth, respectively. DAYBUE net sales were $110 million in Q4 and $391 million for the full year, with 13% and 12% year-over-year growth, respectively.

Publication Date: Mar -01

📋 Highlights
  • Revenue Growth:: ACADIA recorded Q4 adjusted total revenues of $298M (+16% YoY) and $1.08B for 2025 (+14% YoY).
  • Product Performance:: NUPLAZID net sales hit $189M in Q4 (+17% YoY) and $692M annually (+15% YoY), while DAYBUE reached $110M in Q4 (+13% YoY) and $391M annually (+12% YoY).
  • R&D Pipeline:: 4 molecules target $11B peak sales, with 5 Phase II/III studies planned by 2027. Phase II remlifanserin results expected August–October 2026.
  • 2026 Guidance:: Total revenue projected at $1.22B–$1.28B. NUPLAZID: $760M–$790M (10–14% growth); DAYBUE: $460M–$490M (18–25% growth).
  • Financial Strength:: $820M cash balance and $250M noncash tax benefit. Operating margins expected to reach mid-teens by 2028, with CAGR of ~16% over the growth period.

Revenue Growth Drivers

The strong commercial performance of NUPLAZID, with 18% year-over-year growth in new prescriptions in Q4, was a key driver of revenue growth. DAYBUE sales also grew 13% year-over-year in Q4, driven by strong U.S. performance and growing contributions from rest-of-world programs. As Mark Schneyer, Chief Financial Officer, noted, the company's revenue growth is expected to continue, with NUPLAZID net sales expected to reach $760 million to $790 million in 2026, representing 10% to 14% growth over 2025 adjusted net sales.

Valuation Metrics

To understand what's priced into ACADIA Pharmaceuticals' stock, we can look at various valuation metrics. The company's P/E Ratio is 10.64, indicating a relatively reasonable valuation compared to its earnings. The P/S Ratio is 3.88, suggesting that the stock may be slightly overvalued relative to its sales. Additionally, the EV/EBITDA ratio is 25.69, which may indicate a high valuation relative to its earnings before interest, taxes, depreciation, and amortization.

Pipeline and Future Prospects

The company's robust R&D pipeline, with 4 unique molecules targeting large addressable markets with combined peak sales potential of $11 billion, is expected to drive future growth. The company expects to initiate 5 additional Phase II or Phase III studies by the end of 2027. Top-line results from the Phase II study of remlifanserin in Alzheimer's disease psychosis are expected between August and October 2026, which could be a significant catalyst for the stock.

Guidance and Expectations

For fiscal year 2026, the company expects total revenues to be between $1.22 billion and $1.28 billion, representing year-over-year growth. NUPLAZID is expected to have net sales between $760 million and $790 million, driven by expanding volume, while DAYBUE is expected to have net sales between $460 million and $490 million, driven by DAYBUE STIX and growth in named patient supply programs. Analysts estimate next year's revenue growth at 11.5%, which is slightly lower than the company's expected growth rate.

3. NewsRoom

Card image cap

Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

Apr -17

Source: businesswire.com

Card image cap

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Apr -15

Source: businesswire.com

Card image cap

CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?

Apr -14

Source: zacks.com

Card image cap

Mark Schneyer Sells 2,709 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

Apr -09

Source: defenseworld.net

Card image cap

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

Apr -07

Source: businesswire.com

Card image cap

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Mar -28

Source: defenseworld.net

Card image cap

Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback

Mar -25

Source: proactiveinvestors.com

Card image cap

Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback

Mar -25

Source: proactiveinvestors.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.00%)

6. Segments

Innovative Medicines

Expected Growth: 13%

ACADIA Pharmaceuticals Inc.'s Innovative Medicines segment growth is driven by increasing adoption of pimavanserin, a novel treatment for Parkinson's disease psychosis, and strong sales of trofinetide, a potential therapy for Rett syndrome. Additionally, the company's robust pipeline, including candidates for major depressive disorder and Alzheimer's disease, contributes to its growth momentum.

7. Detailed Products

NUPLAZID

NUPLAZID (pimavanserin) is a selective serotonin inverse agonist indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Trofinetide

Trofinetide is a novel, oral, phosphorylated trophin-like molecule being developed for the treatment of Rett syndrome, a rare genetic disorder.

8. ACADIA Pharmaceuticals Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

ACADIA Pharmaceuticals Inc. has a moderate threat of substitutes due to the availability of alternative treatments for central nervous system disorders.

Bargaining Power Of Customers

ACADIA Pharmaceuticals Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the complexity of the pharmaceutical supply chain.

Bargaining Power Of Suppliers

ACADIA Pharmaceuticals Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and the company's dependence on these suppliers.

Threat Of New Entrants

ACADIA Pharmaceuticals Inc. has a high threat of new entrants due to the attractiveness of the pharmaceutical industry and the potential for new companies to enter the market.

Intensity Of Rivalry

ACADIA Pharmaceuticals Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 11.70%
Debt Cost 3.95%
Equity Weight 88.30%
Equity Cost 5.84%
WACC 5.62%
Leverage 13.25%

11. Quality Control: ACADIA Pharmaceuticals Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
ACADIA Pharmaceuticals

A-Score: 5.6/10

Value: 2.1

Growth: 9.0

Quality: 9.1

Yield: 0.0

Momentum: 9.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Arrowhead Pharmaceuticals

A-Score: 4.8/10

Value: 6.0

Growth: 8.6

Quality: 3.3

Yield: 0.0

Momentum: 9.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
TG Therapeutics

A-Score: 4.2/10

Value: 2.0

Growth: 8.1

Quality: 7.7

Yield: 0.0

Momentum: 4.5

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Ultragenyx Pharmaceutical

A-Score: 3.3/10

Value: 6.4

Growth: 4.7

Quality: 3.8

Yield: 0.0

Momentum: 1.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Janux Therapeutics

A-Score: 3.3/10

Value: 7.8

Growth: 3.4

Quality: 4.1

Yield: 0.0

Momentum: 3.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Geron

A-Score: 3.1/10

Value: 6.8

Growth: 5.2

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

22.17$

Current Price

22.17$

Potential

-0.00%

Expected Cash-Flows